Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.36 |
| ▸ | ACACB | O00763 | 4/20 | 0.35 |
| ▸ | ACACA | Q13085 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344703 | 0.93 | HRH3 (0.41) | HRH3PDE10AHTR3AHRH4SCD | |
| SCHEMBL345825 | 0.91 | HRH3 (0.39) | HRH3PDE10AHTR3AHRH4SCD | |
| SCHEMBL345436 | 0.90 | PDE10A (0.40) | HRH3PDE10ASCDTPSAB1TPSD1 | |
| SCHEMBL345081 | 0.90 | ACACB (0.41) | HRH3PDE10AHTR3AHRH4SCD | |
| SCHEMBL346022 | 0.90 | HRH3 (0.39) | HRH3PDE10AHTR3AHRH4SCD | |
| SCHEMBL344986 | 0.89 | SMN1; SMN2 (0.40) | HRH3PDE10AHTR3AHRH4SCD | |
| SCHEMBL239896 | 0.85 | HRH3 (0.46) | HRH3PDE10AHTR3AHRH4SCD | |
| SCHEMBL345765 | 0.83 | HRH3 (0.41) | HRH3PDE10AHTR3AHRH4MCHR1 | |
| SCHEMBL345088 | 0.81 | PDE10A (0.44) | HRH3PDE10ASCDACACBACACA | |
| SCHEMBL344021 | 0.80 | HRH3 (0.40) | HRH3PDE10AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | HRH3 50/4885PDE10A 1799/4885HTR3A 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.